(3S,4R)-1-tert-butyl 3-methyl 4-methoxypyrrolidine-1,3-dicarboxylate | 1428775-90-9

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡咯烷类
• 英文名称: (3S,4R)-1-tert-butyl 3-methyl 4-methoxypyrrolidine-1,3-dicarboxylate
• 英文别名: 1-(tert-Butyl) 3-methyl (3S,4R)-4-methoxypyrrolidine-1,3-dicarboxylate；1-O-tert-butyl 3-O-methyl (3S,4R)-4-methoxypyrrolidine-1,3-dicarboxylate
• CAS: 1428775-90-9
• 化学式: C₁₂H₂₁NO₅
• 分子量: 259.302
• InChiKey: SSXONKFVPDRUNY-IUCAKERBSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.7
• 重原子数：
  18
• 可旋转键数：
  5
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.83
• 拓扑面积：
  65.1
• 氢给体数：
  0
• 氢受体数：
  5

反应信息

• 作为反应物：
  描述：

  (3S,4R)-1-tert-butyl 3-methyl 4-methoxypyrrolidine-1,3-dicarboxylate 在 锂硼氢 、 [2-(di-tert-butylphosphino)-2′,4′,6′-triisopropyl-1,1′-biphenyl][2-((2-aminoethyl)phenyl)]palladium(II) chloride 、 potassium 2-methylbutan-2-olate 、 碳酸氢钠 、 三氟乙酸 作用下， 以 四氢呋喃 、 1,4-二氧六环 、 二氯甲烷 、 水 、 乙酸乙酯 、 甲苯 为溶剂， 反应 8.67h， 生成 1-[(3R,4R)-3-[[[5-氯-2-[[1-甲基-1H-吡唑-4-基)氨基]-7H-吡咯并[2,3-d]嘧啶-4-基]氧基]甲基]-4-甲氧基-1-吡咯烷基]-2-丙烯-1-酮
  参考文献：
  名称：

  Discovery of 1-{(3R,4R)-3-[({5-Chloro-2-[(1-methyl-1H-pyrazol-4-yl)amino]-7H-pyrrolo[2,3-d]pyrimidin-4-yl}oxy)methyl]-4-methoxypyrrolidin-1-yl}prop-2-en-1-one (PF-06459988), a Potent, WT Sparing, Irreversible Inhibitor of T790M-Containing EGFR Mutants

  摘要：

  First generation EGFR TKIs (gefitinib, erlotinib) provide significant clinical benefit for NSCLC cancer patients with oncogenic EGFR mutations. Ultimately, these patients' disease progresses, often driven by a second-site mutation in the EGFR kinase domain (T790M). Another liability of the first generation drugs is severe adverse events driven by inhibition of WT EGFR. As such, our goal was to develop a highly potent irreversible inhibitor with the largest selectivity ratio between the drug-resistant double mutants (L858R/T790M, Del/T790M) and WT EGFR A unique approach to develop covalent inhibitors, optimization of reversible binding affinity, served as a cornerstone of this effort. PF-06459988 was discovered as a novel, third generation irreversible inhibitor, which demonstrates (0 high potency and specificity to the T790M-containing double mutant EGFRs, (ii) minimal intrinsic chemical reactivity of the electrophilic warhead, (iii) greatly reduced proteome reactivity relative to earlier irreversible EGFR inhibitors, and (iv) minimal activity against WT EGFR

  DOI：

  10.1021/acs.jmedchem.5b01633
• 作为产物：
  描述：

  3-甲氧基丙烯酸甲酯 在 氢气 、 palladium(II) hydroxide 、 三氟乙酸 作用下， 以 2-甲基四氢呋喃 、 乙醇 为溶剂， 20.0 ℃ 、103.42 kPa 条件下， 反应 2.0h， 生成 (3S,4R)-1-tert-butyl 3-methyl 4-methoxypyrrolidine-1,3-dicarboxylate
  参考文献：
  名称：

  PYRROLOPYRIMIDINE AND PURINE DERIVATIVES

  摘要：

  本发明涉及式（I）的化合物或其药学上可接受的盐，其中Q、T、V、W、X、Y、Z、环A、R1、R2、R3、R4、R5、R5a、R6、R7、R8、R9、R10、R11、R12、R13、R14、R15、R16、R17和m在此定义。这些新颖的吡咯嘧啶和嘌呤衍生物在哺乳动物中治疗异常细胞生长，如癌症方面具有用处。另外，本发明还涉及含有这些化合物的药物组合物，以及在哺乳动物中治疗异常细胞生长的方法。

  公开号：

  US20130079324A1

文献信息

• [EN] PYRROLOPYRIMIDINE AND PURINE DERIVATIVES<br/>[FR] DÉRIVÉS DE PYRROLOPYRIMIDINE ET DE PURINE
  申请人：PFIZER

  公开号：WO2013042006A1

  公开（公告）日：2013-03-28

  The present invention relates to compounds of formula (I) or pharmaceutically acceptable salts thereof, wherein Q, T, V, W, X, Y, Z, ring A, R1, R2, R3, R4, R5, R5a, R6, R7, R8, R9, R10, R11, R12, R13, R14, R15, R16, R17 and m are defined herein. There novel pyrrolopyrimidine and purine derivatives are useful in the treatment of abnormal cell growth, such as cancer, in mammals. Additional embodiments relate to pharmaceutical compositions containing the compounds and to methods of using the compounds and compositions in the treatment of abnormal cell growth in mammals.

  本发明涉及式(I)的化合物或其药学上可接受的盐，其中Q、T、V、W、X、Y、Z、环A、R1、R2、R3、R4、R5、R5a、R6、R7、R8、R9、R10、R11、R12、R13、R14、R15、R16、R17和m在此定义。这些新型吡咯并嘧啶和嘌呤衍生物在哺乳动物中用于治疗异常细胞增长，例如癌症。其他实施例涉及含有这些化合物的药物组合物以及使用这些化合物和组合物治疗哺乳动物中的异常细胞增长的方法。
• Pyrrolopyrimidine and purine derivatives
  申请人：Cheng Hengmiao

  公开号：US09040547B2

  公开（公告）日：2015-05-26

  The present invention relates to compounds of formula (I) or pharmaceutically acceptable salts thereof, wherein Q, T, V, W, X, Y, Z, ring A, R1, R2, R3, R4, R5, R5a, R6, R7, R8, R9, R10, R11, R12, R13, R14, R15, R16, R17 and m are defined herein. There novel pyrrolopyrimidine and purine derivatives are useful in the treatment of abnormal cell growth, such as cancer, in mammals. Additional embodiments relate to pharmaceutical compositions containing the compounds and to methods of using the compounds and compositions in the treatment of abnormal cell growth in mammals.

  本发明涉及式(I)的化合物或其药学上可接受的盐，其中Q、T、V、W、X、Y、Z、环A、R1、R2、R3、R4、R5、R5a、R6、R7、R8、R9、R10、R11、R12、R13、R14、R15、R16、R17和m在此定义。这些新型吡咯吡嗪和嘌呤衍生物在哺乳动物的异常细胞生长，如癌症治疗中有用。另外，还涉及含有这些化合物的制药组合物以及在哺乳动物的异常细胞生长治疗中使用这些化合物和组合物的方法。
• US9040547B2
  申请人：——

  公开号：US9040547B2

  公开（公告）日：2015-05-26
• [EN] COMBINATION OF AN EGFR T790M INHIBITOR AND AN EGFR INHIBITOR FOR THE TREATMENT OF NON-SMALL CELL LUNG CANCER<br/>[FR] COMBINAISON D'UN INHIBITEUR DE L'EGFR T790M ET D'UN INHIBITEUR DE L'EGFR DANS LE TRAITEMENT D'UN CANCER DU POUMON NON À PETITES CELLULES
  申请人：PFIZER

  公开号：WO2014140989A2

  公开（公告）日：2014-09-18

  This invention relates to a method of treating non-small cell lung cancer by administering a combination of an EGFR T790M inhibitor in combination with a low-dose amount of a panHER inhibitor. This invention also relates to a method of treating non- small cell lung cancer by administering a combination of an irreversible EGFR T790M inhibitor in combination with an EGFR inhibitor.
• [EN] HETEROBIFUNCTIONAL COMPOUNDS AND THEIR USE IN TREATING DISEASE<br/>[FR] COMPOSÉS HÉTÉROBIFONCTIONNELS ET LEUR UTILISATION DANS LE TRAITEMENT DE MALADIES
  申请人：[en]HALDA THERAPEUTICS OPCO, INC.

  公开号：WO2023059605A1

  公开（公告）日：2023-04-13

  The invention provides heterobifunctional compounds, pharmaceutical compositions, and their use in treating disease, such as cancer.